Trial reportClinical and translational gastroenterology2026
The Cirrhosis Medical Home: A Pilot Randomized Trial of a Collaborative Care Model for Patients With Decompensated Cirrhosis.
Trial report in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Palliative Care in Patients with Liver Cirrhosis: A Scoping Review of Identification, Interventions, and Implementation Barriers and Facilitators.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionPatients with decompensated cirrhosis have a high symptom burden and poor outcomes. Collaborative care models that provide coordinated, personalized care could improve outcomes. In this pilot randomized trial, we tested a cirrhosis-centric collaborative care model: the Cirrhosis Medical Home (CMH).
methodsA single-center pilot randomized trial enrolling 40 hospitalized adults with decompensated cirrhosis randomized 1:1 to CMH or usual care. CMH involved 6 months of postdischarge individualized care. Primary outcomes were feasibility-based (enrollment, retention, data completeness). Secondary outcomes at 3 and 6 months included quality of life (SF-36) and healthcare utilization.
resultsOf 205 patients screened, 40 were enrolled. Of the 20 patients randomized to CMH, 13 received postdischarge CMH follow-up. At 3 months, 19 died or had a transplant, 9 were lost to follow-up, and 12 completed the SF-36. At 6 months, an additional 4 died or were lost to follow-up, and 8 completed the SF-36. In intention-to-treat analysis at 3 months, CMH did not improve quality of life. In per protocol analysis at 3 months, CMH improved physical functioning (delta +15 vs -10, P = 0.015), energy/fatigue (+20 vs -5, P = 0.02), and physical component score (+5.5 vs -5.0, P = 0.009). High mortality and readmission rates were seen in both arms but without significant differences. DISCUSSION: Enrollment and retention in a randomized trial of the CMH for posthospitalization management of decompensated cirrhosis is challenging, and patient-reported outcome assessment is limited by high rates of mortality, transplant, and loss to follow-up. These data can be used to inform future design and testing of health services interventions for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.